. Thorax, 33, 479482 Bronchodilatation after inhalation of the antihistamine clemastine. H, receptor blocking antihistamines administered by mouth have not found a clear place in the management of bronchial asthma. We investigated the possibility that higher concentrations of these drugs, administered directly to the bronchial tree, might produce bronchodilatation.
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Twelve asthmatic patients inhaled aerosols generated from solutions of clemastine (0 05%0), salbutamol (0 5%), and placebo. Bronchodilatation was assessed by changes in the forced expiratory volume in one second (FEVY) and peak expiratory flow rate (PEFR) over four hours.
Both clemastine and salbutamol caused significant bronchodilatation. The mean maximum percentage increases in FEV, for clemastine and salbutamol were 21 1 % and 29 2% respectively. The mean maximum percentage increases in PEFR were 31-2% and 35-2% respectively. There was no significant difference in the maximum bronchodilatation produced by the two drugs.
Clemastine, when administered by aerosol inhalation, appears to be an effective bronchodilator.
The role of histamine in the production of acute asthma is controversial. There is evidence that histamine is released in allergic reactions in the lung (Schild et al, 1951) , and challenge studies have shown that the bronchi of asthmatics are more sensitive to histamine than those of nonasthmatics (Curry, 1947; Tiffenau, 1958; Townley et al, 1965) . Oral antihistamine drugs have not found a place in treating asthma, however, and are widely thought to be ineffective (Lancet, 1955) .
Assuming that histamine plays a role in asthma, the therapeutic failure of antihistamines could be due either to the failure to block the H2 receptor sites or to incomplete H, receptor blockade caused by inadequate local concentrations of drugs. Indeed, higher doses of antihistamines, given by mouth or parenterally, have caused bronchodilatation (Popa, 1977) Histamine, along with other mediators of the allergic reaction, has been shown to be released from previous sensitised lung tissue on appropriate allergen challenge (Schild et al, 1951) . Asthmatic patients show an increased bronchial reactivity to inhaled histamine (Curry, 1947; Townley et al, 1965) , and this reactivity is more pronounced in symptomatic than in asymptomatic patients (Cockcroft et al, 1977) . Bhat et al (1976) showed a significant twofold rise in serum histamine concentration five minutes after allergen-induced bronchoconstriction, but not after methacholine-induced bronchoconstriction.
Bruce et al (1976) found a higher plasma histamine concentration in subjects with acute severe asthma than in normal controls, though raised concentrations were also found in patients with other, less acute, chest illnesses.
In-vitro studies with the H1 receptor antagonist mepyramine, (Dunlop et al, 1977) , have shown that complete receptor blockade in isolated bronchial muscle can cause relaxation, even in the presence of histamine. Mepyramine also significantly reduced the contraction of sensitised bronchial muscle in allergen challenge. Oral antihistamines have been recommended for treating asthma but have been found to be relatively ineffective and have failed to find a clear place in its management (Lancet, 1955) . Herxheimer (1948 and 1949) showed that inhalation of mepyramine caused a slight increase in vital capacity in five asthmatic patients, and that inhalation of pyribenzamine and promethazine gave some protection against mild histamine, methacholine, and allergen-induced bronchoconstriction. Pyribenzamine aerosol also caused bronchodilatation in patients with spontaneous asthma. Feinberg et al (1948) showed that aerosols of several antihistamines could prevent histamine-induced bronchoconstriction in guinea pigs. Recent work has shown that inhaled diphenhydramine can prevent histamine-induced bronchoconstriction in asthmatic patients (Casterline and Evans, 1977) . On the other hand, aerosols of antihistamines were found to be irritating, and in concentrations of greater than 2% could themselves cause bronchoconstriction in animals (Hawkins, 1955) .
Clemastine is one of the benzhydrylether group of antihistamine compounds. It is a highly specific H1 receptor antagonist, and has no significant protective effect against bronchoconstriction induced by aerosols of acetylcholine or serotonin (Kallos, 1971) . It causes little central nervous system depression as measured by critical flicker frequency depression (Hedges et al, 1971 ) and hand-eye co-ordination (Day et al, 1972) . As an H1 receptor antagonist it is considerably more potent than promethazine and chlorpheniramine in preventing wheal formation after intradermal injection of histamine and histamine-induced bronchoconstriction in guinea pigs (Hedges et al, 1971) . Our choice of a 005% solution was made after pilot studies, as the highest concentration that did not cause throat irritation with the delivery system used. At this concentration patients were aware of the characteristic taste, but it provoked neither complaints nor problems with cough or throat irritation. No side effects were observed during the study.
The finding that a specific H1 receptor antagonist is an effective bronchodilator with a prolonged action raises again the question of the role of histamine in asthma. While it is possible that part of the bronchodilator effect may be due to anticholinergic properties, the specificity of the compound suggests otherwise. Further studies in histamine and methacholine-induced bronchoconstriction are in hand to resolve this question. Because the onset of bronchodilatation with inhaled clemastine is slower than with salbutamol, clemastine is likely to be of more use for the maintenance management of asthma than for the relief of acute attacks. Its use in conjunction with sympathomimetics and its role in the prevention of exercise-induced asthma are being investigated. 
